Montana has enacted SB535, a law that extends right-to-try provisions by allowing physicians to administer treatments that have cleared FDA Phase 1 trials outside formal clinical trials, provided a state-registered review board approves the protocol and care is delivered at a licensed clinic. Unlike federal right-to-try or expanded access rules, the Montana law permits sponsors and clinics to charge patients for these treatments, addressing what backers call the core funding gap facing biotech firms after early trials.
news.ycombinator.com
· 2026-09-16
Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.
wsj.com
· 2026-09-16
The FDA is investigating a multistate Salmonella outbreak linked to broccoli sprouts, which have been recalled from store shelves. So far, 22 people across four states have fallen ill, with two requiring hospitalization. Health officials are urging consumers not to eat any of the affected products.
fastcompany.com
· 2026-09-11
Despite chaos at the CDC's vaccine advisory panel and RFK Jr.'s anti-vaccine actions as health secretary, updated flu and COVID-19 vaccines have been FDA-approved and are already shipping to pharmacies for the fall season. Major insurers have agreed to keep covering previously recommended vaccines at no cost through at least 2027, and state health officials expect a mostly normal rollout.
arstechnica.com
· 2026-09-09
After his daughter Lucy suffered a brain hemorrhage that left her blind, billionaire Bill Ackman used his connections to secure her advanced care at Mount Sinai and pursue an experimental treatment. In May, the FDA granted her medical team first-time emergency authorization to transplant mitochondria from her leg muscle into her eyes in an attempt to repair her optic nerves. Ackman has since pledged over $400 million to establish an institute focused on longevity and brain health research.
science.slashdot.org
· 2026-09-07
Crystal Temptations issued a recall of its Chocolatey Eyeballs product after the FDA flagged a safety concern, reportedly tied to undisclosed allergens that could pose serious health risks. The candy was sold at major retailers including TJ Maxx and Marshalls across 13 states. The FDA has advised consumers who purchased the product to destroy it rather than consume or return it.
fastcompany.com
· 2026-09-03
Circular has launched its Ring 3 series, succeeding last year's Ring 2, in two versions: a titanium Pro model retaining ECG-based AFib detection, and a lighter Slim model using biocompatible epoxy but lacking ECG tracking. Both rings add vibrating alerts for alarms and reminders and an NFC chip enabling contactless payments directly from the ring.
theverge.com
· 2026-09-03
A week after its US approval for advanced pancreatic cancer, the drug daraxonrasib has shown early promise against non-small cell lung cancer, the most common form of the disease. In a small trial published in the New England Journal of Medicine, tumors shrank in over 30% of patients whose cancers carried mutations in RAS family proteins and who had already failed other treatments. A larger randomized trial comparing daraxonrasib to standard chemotherapy is now underway.
nature.com
· 2026-09-02
The FDA has designated a recall of Mild Guacamole and Salsa Dips sold at Whole Foods Market as Class I, its most severe category, due to possible salmonella contamination. The recall, initiated August 7, covers 10 product varieties and nearly 13,000 units with best-by dates between August 7 and August 16, 2026, and is tied to contaminated jalapenos distributed nationwide by a Mexican supplier.
fastcompany.com
· 2026-08-31
Revolution Medicines received FDA approval this week for a pancreatic cancer pill, a milestone that comes after the company fielded acquisition interest from larger pharmaceutical firms but chose to remain independent. The decision allowed it to bring the drug through regulatory approval on its own rather than as part of a larger acquirer's pipeline.
wsj.com
· 2026-08-28
The FDA has cleared daraxonrasib, a new drug for pancreatic cancer, after a large clinical trial found patients on the treatment survived roughly twice as long as those receiving standard chemotherapy. The approval gives doctors a new option for a disease long known for poor treatment outcomes.
gizmodo.com
· 2026-08-26
The FDA has approved Rasonque (daraxonrasib), a once-daily pill designed to block multiple mutated forms of the RAS protein that drive most pancreatic adenocarcinoma tumors. It is cleared for adults with metastatic disease who have already tried one systemic treatment or cannot tolerate combination chemotherapy, and the agency says it acted ahead of its original review timeline.
fda.gov
· 2026-08-26
GoKawiil